Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-17-308380
Filing Date
2017-10-12
Accepted
2017-10-12 07:07:57
Documents
9
Period of Report
2017-11-30
Effectiveness Date
2017-10-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A d462900ddef14a.htm DEF 14A 830264
2 GRAPHIC g462900g05h24.jpg GRAPHIC 25440
3 GRAPHIC g462900g08i11.jpg GRAPHIC 32420
4 GRAPHIC g462900g24p45.jpg GRAPHIC 33369
5 GRAPHIC g462900g30n56.jpg GRAPHIC 1930
6 GRAPHIC g462900g35h68.jpg GRAPHIC 33573
7 GRAPHIC g462900g42x55.jpg GRAPHIC 27891
8 GRAPHIC g462900g82f46.jpg GRAPHIC 25830
9 GRAPHIC g462900snap1.jpg GRAPHIC 850
  Complete submission text file 0001193125-17-308380.txt   1081877
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 000-26642 | Film No.: 171133762
SIC: 2835 In Vitro & In Vivo Diagnostic Substances